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Background: Hematopoieticic stem cell transplantation is the only therapeutic option that can cure thalassemia
disease. Reduced intensity hematopoietic stem cell transplantation (RI-HSCT) has demonstrated a high cure rate
with minimal complications compared to other options. Because RI-HSCT is very costly, economic justification for its
value is needed. This study aimed to estimate the cost-utility of RI-HSCT compared with blood transfusions
combined with iron chelating therapy (BT-ICT) for adolescent and young adult with severe thalassemia in Thailand.
Methods: A Markov model was used to estimate the relevant costs and health outcomes over the patients’
lifetimes using a societal perspective. All future costs and outcomes were discounted at a rate of 3% per annum.
The efficacy of RI-HSCT was based a clinical trial including a total of 18 thalassemia patients. Utility values were
derived directly from all patients using EQ-5D and SF-6D. Primary outcomes of interest were lifetime costs, quality
adjusted life-years (QALYs) gained, and the incremental cost-effectiveness ratio (ICER) in US ($) per QALY gained.
One-way and probabilistic sensitivity analyses (PSA) were conducted to investigate the effect of parameter
uncertainty.
Results: In base case analysis, the RI-HSCT group had a better clinical outcomes and higher lifetime costs. The
incremental cost per QALY gained was US $ 3,236 per QALY. The acceptability curve showed that the probability of
RI-HSCT being cost-effective was 71% at the willingness to pay of 1 time of Thai Gross domestic product per capita
(GDP per capita), approximately US $ 4,210 per QALY gained. The most sensitive parameter was utility of severe
thalassemia patients without cardiac complication patients.
Conclusion: At a societal willingness to pay of 1 GDP per capita, RI-HSCT was a cost-effective treatment for
adolescent and young adult with severe thalassemia in Thailand compared to BT-ICT.
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Thalassemia is one of the important hematological
diseases in Thailand. Thalassaemia patients have
produced abnormal haemoglobin, leading to anaemia.
The prevalence of thalassemia carriers in Thailand was
reported as 30%-40%. About 1% of Thai population,
approximately 65,000 people, have thalassemia [1]. The
standard treatment of severe thalassemia is regular blood
transfusion combined with iron chelating therapy
(BT-ICT) to prevent iron overload. BT-ICT treatment
has to be given subcutaneously for 8 to 12 hours per
days, 5 to 7 days per week. This arduous treatment
regimen and the high cost can lead to poor compliance
and difficulty in patients’ life which could affect the effec-
tiveness of the treatment. Adult thalassemia patients
(age 17 or older) have more advanced disease and
treatment related organ complications mainly due to
prolonged exposure to iron overload [2].
At present, the only curative treatment existing for
severe thalassemic patients was hematopoietic stem cell
transplantation (HSCT) [2]. However; HSCT was used
with limitations because of a number of reasons. Com-
pared to younger patients, the transplantation associated
mortality and rejection rates, in patients aged more than
17 years old with iron-overload related organ damage,
are as high as 40% and 16%, respectively [2]. Moreover,
the percentages of human leukocyte antigen (HLA)-
matched donor were as low as 25% for patient’s relative
donor and 1 out of 50,000 in the unrelated donors [3-5].
Reduced intensity hematopoietic stem cell transplant-
ation (RI-HSCT) is a new preparative regimen for high
risk thalassemia patients especially adolescent and adult.
RI-HSCT has been demonstrated to be an effective strategy
to reduce the toxicity of transplantation with low incidence
of graft rejection. This novel approach is a promising
alternative for reducing the risk of life-threatening
complications and increasing the number of patients
successfully cured with an allograft [6]. Reduced
intensity preparative regimens are demonstrated with
lower morbidity and mortality after transplantation
[7]. In Thailand, Hongeng et al. [8] performed RI-HSCT
in 8 patients with Class 3 Lucarelli. Seven patients
received peripheral blood stem cells (PBSCs) from
HLA-matched sibling donors while one patient
received from haploidentical mother. An engraftment
of donor cells was observed in all patients. Six out of
8 patients had stable full donor engraftment. There
were no deaths or grade 3–4 acute graft-versus-host
disease (GvHD) among these patients.
Although RI-HSCT has demonstrated efficacy, its pro-
cedure is complex and incurs high expenditure especially
during the first three years of treatment. Given the high
cost of RI-HSCT, there remains an important question to
be answered from a policy maker perspective whetherRI-HSCT is worth the money spent and increase qual-
ity of life of patients. This study examines the potential
cost-utility of RI-HSCT compared to BT-ICT in the
treatment of patients with severe adolescent and young
adult thalassemia.
Methods
Overall description of cost-utility analysis methodology
We used a markov model to simulate severe thalassemia
patients receiving RI-HSCT compared to BT-ICT, which
is a standard practice of thalassemia treatment. The
study was undertaken using a societal perspective as
recommended by the Thailand’s health technology
assessment guidelines [9]. We performed a cost-utility
analysis with incremental cost per QALY gained.
The model simulates for the life time horizon.
Clinical effectiveness and economic outcomes was
directly obtained from an ongoing clinical investigation of
RI-HSCT in 18 thalassemia patients in Thailand. The
simulated cohort’s characteristics of the model were
based on the characteristics of 18 patients. Ethical ap-
proval was granted by the Committee on Human
Rights Related to Research Involving Human Subjects,
Mahidol University.
Economic model
A Markov model, as shown in Figure 1, was used to esti-
mate the relevant costs and health outcomes. The health
states of patients assigned to RI-HSCT consisted of eight
states, which were categorized into five groups to mimic
the natural history of thalassemia and clinical practice;
(i) the first year of RI-HSCT consisted of four states
[Q1-Q4], with the length of three months each. The
first six months [Q1-Q2] is the period with the highest
costs, highest graft rejections and worst quality of life
(QoL). We assumed that the rejection rate in this period
is consistent. The remaining six months [Q3-Q4] is when
the patients needed close follow up in order to monitor
side effects, resulting in more frequent visits. No graft
rejection occured in this period; (ii) The second and third
year of RI-HSCT [Iron chelation] was when patients had
higher costs due to either regular phlebotomy or chelation
therapy and immunosuppressive therapy; (iii) following
years after successful RI-HSCT [Post RI-HSCT] (iv)
RI-HSCT failure resulting in a switch to BT-ICT.
After graft rejection, patients were to receive blood
transfusions and subcutaneous infusion iron chealtion
therapy only. Since cardiac disease is the major cause
of death, we constructed the BT-ICT health state with
two sub-health states: thalassemia patients without
complication and thalassemia patients with cardiac
complication; and (v) death Blood transfusion dependent
patients had two health states (i.e. BT-ICT and death).
The arrows represent the possible transitions from one
Figure 1 Schematic diagram of the markov model. Each thalassemia patient has two treatment options (RI-HSCT and BT-ICT) The Markov
model consists of eight health states and patients receiving RI-HSCT can transition through each of these health states whereas BT-ICT patients
can be in either alive BT-ICT state or death state. The cycle length is one year with a 99-year time horizon. RI-HSCT: Reduced intensity
hematopoietic stem cell transplantation; BT-ICT: Blood transfusion combined with iron chelating therapy.
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within all health states as they typically took far less than
one year to resolve. The simulation estimated the costs
and health outcomes over a lifetime time horizon. All
transition probabilities, costs and outcomes variables are
shown in Table 1.Description of reduced intensity hematopoietic stem cell
(RI-HSCT)
The first cohort of 8 patients received conditioning regi-
men as described previously [8] and the remaining 10
patients received a new reduced intensity conditioning
regimen consisting of intravevous busulfan 130 mg/m2
for 4 days, fludarabine 35 mg/m2 for 6 days and antithy-
mocyte globulin (ThymoglobulinW) 1.5 mg/kg for 4
days and they also received fludarabine 30 mg/m2
for 5 days and dexamethasone 25 mg/m2 for 5 days
1 month prior to transplant for immunosuppression
rationale. The reduced intensity regimen was designed for
patients who were classified as having Lucarelli class 3. All
these patients were given hydroxyurea 20 mg/kg/d ≥ 3
months before BMT to decrease erythroid expansion and
thus prevent graft rejection [19-21].
Stem cell grafts are prepared by the following
procedures. T-cell nondepleted peripheral blood stem
cell graft was infused on day 0. Only 1 patient
received purified CD34+ cells that were derived from
2 antigens and HLA-mismatched maternal peripheral
blood stem cells with additional CD3+ cells to a total
of 1 × 105 CD3+ cells/kg [21]. These purified CD34+
cells were obtained with Clinimacs (Miltenyi, Bergisch,Germany). All donors received subcutaneous granulo-
cyte colony-stimulating factor 10 μg/kg/d for 4 days be-
fore leukapheresis procedures.
For graft-versus-host disease (GVHD) prophylaxis,
Three days before transplantation, patients received
cyclosporin at a dose that was adjusted to achieve a
plasma concentration of 250–350 ng/mL or tacrolimus
at a dose that was adjusted to achieve a plasma concen-
tration of 5–15 ng/mL. All received a short course of
methotrexate [22]. Engraftment Criteria; 3 consecutive
days with an absolute neutrophil count >.5 × 109/L or 7
consecutive days with a platelet count >20 × 109/L with-
out transfusion were taken as evidence of engraftment.
In order to prevent Pneumocystis carinii pneumonia,
patients received a preventive regimen of trimethoprim-
sulfamethoxazole (cotrimoxazole) at 5 mg/kg/d divided
into 2 doses for 3 days a week. Cytomegalovirus (CMV)
and Ebstein-Barr virus (EBV) reactivations were moni-
tored by CMVand EBV viral loads. Patients with a CMV viral
load >103 copies/mL were treated with ganciclovir [23] and
intravenous immunoglobulin [23] and patients with an EBV
viral load >103 copies/mL were treated with rituximab [24].Effectiveness data
Effectiveness of RI-HSCT
A total of 18 patients receiving RI-HSCT at Ramathibodi
hospital between 2003 and 2011 were used a source of
clinical effectiveness of the intervention. Five cases were
patients with homozygous β-thalassemia while the
remaining 13 were β-thalassemia/hemoglobin E. The
time to death and time to failure were directly derived
Table 1 Input parameters used in the model
Variable Mean (SE) Sources
Clinical Variable (Transitional Probability)
RI-HSCT
Q1 state –> Death Vary Cohort, MOPH [10]
Q1 state –> BT-ICT 0.00003 Cohort
Q2 state –> Death Vary Cohort, MOPH [10]
Q2 state –> BT-ICT 0.0003 Cohort
Q3 state –> Death Age-specific
Mortality
MOPH [10]
Q3 state –> BT-ICT 0.00 Assumption
Q4 state –> Death Age-specific
Mortality
MOPH [10]
Q4 state –> BT-ICT 0.00 Assumption
Iron chelation state –> Death Age-specific
Mortality
MOPH [10]
Iron chelation state--> BT-ICT 0.00 Assumption
Post RI-HSCT –> Death Age-specific
Mortality
MOPH [10]
Post RI-HSCT–> BT-ICT 0.00 Assumption
BT-ICT (Severe Thalassemia patients)
BT-ICT Thal –> BT-ICT Thal with
cardiac
0.0114 Borgna-Pignatti C et al.
[11]
BT-ICT Thal –> Death Vary MOPH [10], Delea et al.
[12], Gabutti & Piga [13]
BT-ICT Thal with
cardiac –> Death
Vary MOPH [10] and
Chouliaras G [14]
Cost Variable (convert to US $) *,!
RI-HSCT
Pre-BMT
Direct Medical Cost 1,330 (438) Hospital Database#
Direct Non Medical Cost 75 (21) Survey
Indirect Cost 175 (42) Survey
Q1 state
Direct Medical Cost 1,226 (169) Hospital Database#
Direct Non Medical Cost 458 (51) Survey
Indirect Cost 945 (105) Survey
Q2 state
Direct Medical Cost 1,710 (381) Hospital Database#
Direct Non Medical Cost 335 (41) Survey
Indirect Cost 691 (85) Survey
Q3 state
Direct Medical Cost 1,628 (538) Hospital Database#
Direct Non Medical Cost 259 (30) Survey
Indirect Cost 535 (62) Survey
Q4 state
Direct Medical Cost 878 (282) Hospital Database#
Direct Non Medical Cost 253 (32) Survey
Indirect Cost 522 (66) Survey
Iron chelation state
Direct Medical Cost 1,120 (238) Hospital Database#
Table 1 Input parameters used in the model (Continued)
Direct Non Medical Cost 539 (112) Survey
Indirect Cost 1,111 (230) Survey
Post RI-HSCT state
Direct Non Medical Cost 1,548 (411) Hospital Database#
Direct non Medical Cost 299 (146 Survey
Indirect Cost 617 (301) Survey
BT-ICT (Severe Thalassemia patients)
Severe thalassemia patients
without cardiac complications
Direct Medical Cost 1,187 (137) Riewpariboon et al.
[28]
Direct Non Medical Cost 1,240 (232) Leelahavaring et al.
[29]




Direct Medical Cost 1,187 (137) Riewpariboon et al.
[28]
Direct Non Medical Cost 1,240 (232) Leelahavaring et al.
[29]




Q1 state 0.59 (0.30) Survey
Q2 state 0.59 (0.30) Survey
Q3 state 0.59 (0.30) Survey
Q4 state 0.59 (0.30) Survey
Iron chelation state 0.88 (0.06) Survey





0.61 (0.03) Osborne et al. [33]
Severe thalassemia patients with
cardiac complications
0.46 (0.02) Osborne et al. [33]
RI-HSCT: Reduced intensity hematopoietic stem cell, BT-ICT: Blood transfusion
combined with subcutaneous iron chelating therapy, Pre-BMT: Pre-bone
marrow transplantation.
* ($US, year 2011 value).
# Charges were converted to cost using a cost-to-charge ratio of 1.37 which
was derived from Ramathibodi hospital for base-case analysis and 0.8-1.5 [27]
for sensitivity analysis.
! Costs in Q1-Q4 is calculated for 3 month period, while costs beyond Q4 are
on an annual basis.
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with Exponential Regression [25]. This is to yield which
is the cumulative hazard.
Ht ¼ λtγ
where Ht is the cumulative hazard; λ (lambda) is the
scale parameter; t is time in days; and ancillary or γ
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instantaneous hazard rate (ht).
The survival function, (St) which describes the probability
of survival at time t
St ¼ exp htð Þ
The transitional probability of the event of interest
(death or failure) Probability of RI-HSCT is calculated
using St and St − u being estimated from the following
formula (where u is the cycle length of the model)
P ¼ 1 St
Stu
Due to the limited number of patients, the probability
of death derived from RI-HSCT patients would not
reflect the true mortality rate. We calculated the prob-
ability to death in terms of Thai population by conver-
ting the probability of death from the cohort into rate of
death, then adding the age-specific Thai mortality rate
[10] and convert the result back into probability in order
to reflect all population. Because there were no cases of
failure of RI-HSCT after six months of treatment, we
assumed zero probability of failure in subsequent
periods. Based on our cohort, 2 of 18 patients were
failed of RI-HSCT. One was failed within 50 days,
while another was 131 days. Thus, we applied the
zero probability of failure in the model after 180 days
of RI-HSCT.
Effectiveness of BI-ICT
For patients receiving BT-ICT, we estimated the risk of
death based on the multiplication of Thai age-specific
mortality [10] and relative risk of 3.9. This relative risk
value was derived by Delea et al. [12] using the cohort
data of 257 thalassaemia patients reported in a study by
Gabutti and Piga et al. [13]. The probability of transi-
tioning from thalassaemia without cardiac complication
to thalassaemia with a cardiac complication was derived
from a cohort study of 1073 thalassaemia patients [11].
We converted annual risk of having cardiac complica-
tions from a heart failure-free probability. For the risk of
death for patients with cardiac complications, we com-
bined the age-specific mortality rate for patients with
thalassaemia without complications and the age specific
mortality rate related to cardiac diseases. The latter mor-
tality rate was obtained from a cohort study that
followed up 648 thalassaemia in order to determine the
risk of cardiac related death almost 28 years [14]. Based
on the cohort of 18 patients, no one received RI-HSCT
more than once. Therefore, in the model it was assumed
that if the RI-HSCT failed, patients would receive
BT-ICT for the rest of their lives.Cost data
As this study was undertaken using the societal perspec-
tive, each group consisted of direct medical costs, direct
non medical costs, and indirect costs. All costs were
converted and reported in 2011 US $ (US $1= 30.50
THB [26]) using the consumer price index (CPI) [15].
We divided costs for RI-HSCT groups into 2 parts which
were cost of pre-bone marrow transplantation (Pre-BMT)
and costs of transplantation and follow up. Direct medical
costs were estimated using micro-costing approach [16].
Direct medical costs for pre-bone marrow transplantation
included laboratory tests and investigation from patients
and donors were obtained from hospital databases. Direct
medical costs for transplantation and follow up were
calculated starting from the first date of patient’s admis-
sion during pre-transplantation management. Costs were
divided in line with the heath states in the model, for
example; costs in the first year [Q1-Q4] were estimated in
3 month-period, while costs of iron chelation and post
RI-HSCT were calculated annually. Direct medical
costs for RI-HSCT group were obtained from two
data sources. First, costs of patients receiving RI-HSCT
were retrieved from a hospital database at a teaching
hospital between 2003 and 2011. Cost to charge ratio was
used to convert hospital charges to cost by multiplying
charges to cost to charge ratio. Conversion of hospital
charge to costs is a reasonable trade-off between accuracy
and the resources used for costing [16]. Charges were
converted to cost using a cost-to-charge ratio of 1.37
which was derived from Ramathibodi hospital for base-
case analysis and 0.8-1.5 [27] for sensitivity analysis. Other
direct medical costs for example: out of pocket expenses
which related to medications were collected using ques-
tionnaires. Both direct non-medical and indirect costs for
RI-HSCT groups were collected by interviewing severe
thalassemia patients and their caregivers at Ramathibodi
hospital after obtaining informed consent. Eighteen
RI-HSCT patients were interviewed by questionnaire.
Direct non-medical costs included; costs of transportation,
meals, accommodation, facilities, other self care expenses
and informal care. Indirect costs referred to productivity
losses due to sick leave. Resource cost parameters are
presented in Table 1.
Because of the lack of separated costs data for severe
thalassemia patients with or without cardiac complica-
tions, we decided to use costs of severe thalassemia
patients based on a study of Leelahavarong et al. and
Riewpariboon et al. as cost inputs in our model. The
costs for severe thalassemia patients were obtained from
two literature studies. First, direct medical costs were
derived from a cost analysis by Riewpaiboon et al. [28]
which is the largest cost-of-illness of thalassemia patients
study in Thailand. The study population consisted of 124
severe thalassemia patients. Mean direct medical costs per
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and indirect costs, we obtained data from Leelahavarong
et al. [29] which were collected from severe thalassemia
patients (same as our study). This study interviewed 28
severe thalassemia patients who received hyper-blood
transfusion and iron chelation treatment at Ramathibodi
hospital using questionnaire. Direct non-medical costs
were estimated US $ 1,240 (SE = 232) and US $ 636
(SE = 221) for indirect costs.Utility data
We measured health-related quality of life of RI-HSCT
patients using SF-36V2 [Thai version of the SF-36
(short-form survey) version 2.0] and EQ5D (EuroQoL
EQ-5D). In Thailand, the validated official Thai version
of EQ-5D is available. The answer from Thai version of
EQ-5D questionnaire can be converted into 0–1 utility
score by Thai preference score for EQ-5D health state
[30]. Because of its practicality and accepted reliability,
EQ-5D is the recommended utility measurement
method in guideline of Thailand’s health technology
assessment [9]. The other advantage of EQ-5D is that
it is easier for patients to answer the questionnaires
compared to decision making in preference elicitation
techniques. We used utility derived from EQ-5D as
main analysis and SF-36 as sensitivity analysis. The
SF-36 is a multipurpose, short-form health survey
with only 36 questions. It yields an eight-scale profile
of scores as well as physical and mental health sum-
mary measures [17]. The questionnaire consists of 36
items that cover 8 aspects of health-related quality of
life including physical functioning, role limitations
due to physical problems, social functioning, bodily
pain, general mental health, role limitation due to
emotional problems, vitality (energy/fatigue) and gen-
eral health perceptions. SF-36V2 [31] (Thai version) is
a widely used instrument with high validity and reliability.
The utility scores were estimated via SF-6D derived from
the SF-36. SF-6D was converted using SF-36 data at the
individual level to single utility score using regression
model [32]. We adopted the approach of Delea et al.
[12] in deriving utility values for severe thalassemia
patients without cardiac complication from the litera-
ture. The utility value was 0.61 (0.66). These values
were taken from an Australian study [33], using a
time trade-off (TTO) exercise to elicit utility values
from a sample of 120 individuals of various demo-
graphic characteristics. For health state with cardiac
complications, we also adopted the approach of Delea
et al. [12] and deducted a utility of 0.15. This value
was obtained from a cohort study which estimatd a
disutility value of heart failure based on 1365 random
samples of US adults in a community [34].Cost-utility analysis
Primary outcomes of interest were lifetime costs, QALYs
gained, and ICER in US ($) per QALY gained. For
base-case analysis, we calculated the expected lifetime
costs and outcomes from each group of treatment.
All future costs and outcomes were discounted at a
rate of 3% per annum [35]. The results were presented as
ICER for RI-HSCT vs BT-ICT
ICER ¼ CostRIHSCT  CostBTICT
QALYsRIHSCT  QALYsBTICT
The interpretation of cost-effectiveness of our findings
is based on the statement of the Subcommittee for
Development of the National List of Essential Drugs and
the Subcommittee for Development of the Health
Benefit Package and Service Delivery of the NHSO in
2007. The subcommittee set up the societal willingness to
pay (WTP) threshold in Thailand to one to three times
per capita Gross Domestic Product (GDP) [36], approxi-
mating US $ 4,210 (128,403 THB) to US $ 12,263
(385,209 THB) per QALY gained in 2010 [18]. These
values are in accordance with the recommendations of the
Commission on Macroeconomics and Health of World
Health Organization, suggesting that health technologies
with the incremental cost-effectiveness ratio (ICER) below
the per capita GDP are considered very cost-effective,
while those between one and three times per capita GDP
being cost-effective, and ICER above three times per
capita GDP indicate that a health technology is not
cost-effective [37].
Sensitivity analysis
One-way sensitivity analyses were performed to investi-
gate the effects of altering parameters within plausible
ranges including survival parameters, time to failure
parameters, all costs, utilities, costs to charge ratio and
discounting rate. The results of one-way sensitivity were
presented using a tornado diagram. For the sensitivity
analysis of discounting rate, we used the recommenda-
tion from WHO [35] including 0% discount costs and
health outcomes, 0% discount health outcomes and 6%
discount costs, and 6% discount cost and health out-
comes. In addition, a probabilistic sensitivity analysis
(PSA) was conducted to examine the effect of all parameter
uncertainty simultaneously using a Monte Carlo simulation
performed by Microsoft Excel 2003 (Microsoft Corp.,
Redmond, WA) [25]. The distributions of each probability
were assigned following [38]: (a.) probability and utility
parameters, in which their values ranged between zero and
one, were specified to beta-distributions, (b.) costs, their
characters were positively skewed and values were above
zero, were assigned to gamma-distributions, and (c.)
survival parameters were given to a log-normal distribution.




Mean + SD 13.7 + 2.7
Range 9 – 18







Lower than primary school 3 (16.7)
Primary school 1 (5.6)
Secondary school 7 (38.9)
College 2 (11.1)
Undergraduate school 5 (27.7)
Transplant characteristic
Thalassemia type
homozygous beta-thalassemia 5 (27.8)




Mean + SD 1.3 + 0.6
Range 1 – 3
CSMBS: Civil servant medical benefit scheme; UC: Universal coverage;
PBSC: Peripheral blood stem cell.
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the simulation to give a range of values for total
costs, outcomes, and ICERs. Results of the PSA were
presented as cost-effectiveness acceptability curves.
The expected net monetary benefit (NMB) was
calculated for each WTP threshold in Thailand (one
and three GDP per capita).
Results and discussion
Clinical effectiveness
A total of 18 patients receiving RI-HSCT were included
in this study. Mean age was 13.7 years; range 9–18 years.
Peripheral Blood Stem Cell (PBSC) was used as sources
for stem cell transplantation for all patients. Patients
were classified as class III according to Lucarelli or
Pesaro classification [2]. Of 18 patients, two patients
have comorbidity diseases (hypothyroid and diabetes).
The average duration of follow-up is 2 years with the
range from 1 to 8 years. Demographic description of
these patients was shown in Table 2. Based on our
cohort, 2 of 18 patients (11%) were failed of RI-HSCT.
One was failed within 50 days, while another was
131 days. Only one patients died of transplantation-
related complications (namely pulmonary infection).
The Kaplan-Meier curve was displayed in Figure 2.
Cost-utility analysis
Our base-case analysis demonstrated the estimated life
time cost for BT-ICT and RI-HSCT as US $ 73,928
(2,254,806 Thai baht) and US$ 114,000 (3,476,988 Thai
baht), respectively, while the estimated QALYs were
14.11, and 26.49 QALYs, respectively. (Table 3) Com-
pared to BT-ICT, the conventional therapy of severe
thalassemia with hyper-blood transfusion and iron-
chelating therapy, an incremental cost per QALY gained
for RI-HSCT was US$ 3,236 per QALY.
Sensitivity analysis
A series of one-way sensitivity analyses as shown in
Figure 3 showed that the most influential parameter was
utility of severe thalassemia patients without cardiac
complication patients. When varying the utility of severe
thalassemia patients without cardiac complication
patients from 0.3 to 0.9, the cost-utility ratio was shifted
to US$ 1,843 and 5,364. Discounting rate was the second
influential parameter.
When varying the discounting rate from 3% to 0% and
6%, the cost-utility value was shifted to US$ 1,792 and
5,087, respectively. When varying the cost to charge
ratio from 0.8 to 1.5, the cost-utility ratio was shifted to
US$ 641 and 3,689.
The result of 1,000 simulations of PSA showed that
RI-HSCT was estimated to have higher cost and more
effective compared to conventional therapy (BT-ICT)(Figure 4). Cost effectiveness acceptability curves
(CEAC) showed the threshold values of US$ 4,210
(128,403 THB) and US$ 12,263 (385,209 THB), RI-HSCT
have 71.3% and 99.9%, respectively of being cost-effective
when compared with BT-ICT (Figure 5).Discussion
Our findings demonstrate that RI-HSCT is highly
effective and very cost-effective for adolescent and
adult thalassemia patients given the consideration of
local context on the willingness to pay value. The
high success rate of this transplantation is highly
regarded as a strong evidence for considering RI-HSCT
as a therapeutic alternative for this population. On the
overall basis, this study provides key relevant information
aiding policy makers to make informed decision making
regarding resource allocation.
Clinical effectiveness of RI-HSCT is a key factor
driving this intervention to be cost-effective. The high
effectiveness rate, demonstrated as low treatment failure
Figure 2 Estimates of survival and graft rejection for 18 patients receiving RI-HSCT. RI-HSCT: Reduced intensity hematopoietic stem
cell transplantation.
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RI-HSCT. First, we used rigorous criteria to select
patients for RI-HSCT. We selected only patients with
consistent blood transfusion and iron chelation therapy
for 1–2 years before transplantation. Second, we had a
good pre-transplantation management which was the use
of effective medications to suppress bone marrow expan-
sion or alloimmunization from previous multiple blood
transfusions such as hydroxyurea, fludarabine and dexa-
methasone. Previous studies showed that these medica-
tions could increase the success rate of transplantation
[39]. At present, the moving target of thalassemia
treatment is focused on transplantation; a number of
cost-effectiveness studies of this treatment have further
improved. While the improvement in non-transplant
therapy has been a relatively slower process.
The findings of being cost-effective are robust across
all sensitivity analyses performed. Our study revealed
that the ICERs were sensitive to utility values of BT-ICTTable 3 Results from base-case analysis
Outcome measure RI-HSCT BT-ICT RI-HSCT vs
BT-ICT
Costs*
Direct Medical Cost 83,733.58 28,651.11 55,082.47
Direct Non Medical Cost 9,877.00 29,928.83 −20,541.83
Indirect Cost 20,389.58 15,347.89 5,041.69
Total 114,000.16 73,927.83 40,072.33
QALYs 26.50 14.11 12.38
Cost per QALY gained 3,236.37
QALY = Quality adjusted life year; RI-HSCT: Reduced intensity hematopoietic stem
cell; BT-ICT: Blood transfusion combined with subcutaneous iron chelating therapy.
* ($US, year 2011 value).patients, discount rate and cost to charge ratio. However,
there remains unchanged in terms of direction of overall
research findings. The cost-effectiveness acceptability
curves suggest that the probability that the RI-HSCT
being cost-effectiveness compared to usual care is
approximately sixty-four percent using one GDP and
ninety-nine percent when using three GDP per capita.
To our knowledge, our study is the first study that
determine the cost-effectiveness of RI-HSCT in adoles-
cence and young adult with severe thalassemia patients.
A number of clinical studies of RI-HSCT have demon-
strated its effectiveness in both pediatric and adult thal-
assemia population [6-8], but there is a lack of economic
evidence of RI-HSCT. There was only one previously
published cost-effectiveness study of HSCT [29]. They
reported that HSCT to severe thalassemia patients with
related or un-related donors was likely to be cost-
effective only when provided to patients aged up to
10 years. Our study had demonstrated that RI-HSCT
may be a viable option for adolescent and adult severe
thalassemia patients who are older than 10 due to the
high clinical benefits and cost-effective treatment.
We believe that our findings are highly valid and con-
textually relevant because we used local data as much as
possible in our analysis, as illustrated by the following
examples. First, even though there is a lack of survival
data for patients treated with blood transfusions in
Thailand, we adjusted the mortality rate of BT-ICT
patients [33] by incorporating Thai age-specific mortality
rate to reflect Thai population. Secondly, we obtained data
on direct medical costs, direct non-medical costs and
indirect costs of patients receiving BT-ICT from one of
the largest cohort studies of thalassemia patients in
Figure 3 A series of one-way sensitivity analyses comparing RI-HSCT to BT-ICT. RI-HSCT: Reduced intensity hematopoietic stem cell
transplantation; BT-ICT: Blood transfusion combined with iron chelating therapy.
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reliable local sources i.e. national reimbursement rate
specified by MOPH and Drugs and Medical Supplies Infor-
mation Center (DMSIC), Ministry of Public Health. Most
importantly, our study was conducted in accordance with
pharmacoeconomic guideline in Thailand [9]. The societal
perspective undertaken in our analysis was the most widely
recommended perspective. Fourth, to our knowledge, thisFigure 4 Probabilistic sensitivity analysis of the incremental costs and
effectiveness plane. RI-HSCT: Reduced intensity hematopoietic stem cell t
therapy; QALYs: quality adjusted life-years.study is the first study in Thailand directly collected quality
of life from RI-HSCT patients. Moreover, we derived utility
values using Thai preference score for EQ-5D. These make
our results more reliable for Thai context.
A number of limitations in our study deserved discus-
sion. First, the survival data and transition probabilities
for RI-HSCT patients as well as the direct medical costs
of RI-HSCT were obtained from the small number ofeffectiveness (QALYs) for RI-HSCT vs BT-ICT presented on a cost-
ransplantation; BT-ICT: Blood transfusion combined with iron chelating
Figure 5 Cost effectiveness acceptability curve showing the probability that using RI-HSCT is cost-effective compared with BT-ICT.
RI-HSCT: Reduced intensity hematopoietic stem cell transplantation; BT-ICT: Blood transfusion combined with iron chelating therapy.
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innovative treatment of thalassemia in Thailand, it was
offered only to a few numbers of patients receiving care
at a couple of hospitals in Bangkok. Second, the sensitiv-
ity analysis indicated that the ICER per QALY gained
was most sensitive to changes in the utility of BT-ICT
patients which this study obtained from foreign data
(UK). This is identified as an area where further studies
using local data are needed. Third, the direct medical
costs of the interventions were obtained from a single
hospital. RI-HSCT is the innovation intervention to cure
thalassemia patients and need expert to look after these
patients. RI-HSCT patients need to be followed up regu-
larly at the same hospital so all costs could be collected
in a single hospital database. However, using a single
hospital database could however underestimate the true
costs of blood transfusions, as patients might receive
these in a number of different hospitals.
These findings are very favorable and could be inter-
preted by policy makers as paramount evidence to
strongly endorse the decision to support the program;
however, most of the decision making generally cannot
be made based solely on a cost-effectiveness analysis.
Before deciding to support to reimburse RI-HSCT in
the any health benefit package, decision makers may beinterested in knowing other important issues about the
characteristics of the populations that benefit from the
transplantation. Then, budget impact analysis should be
done along with the implementation suggested, in order
to estimate the total budget needed. Moreover, preparing
health care system including facilities, resources and
treatment knowledge should be transferred to various
centers to further expand the chance for the patients to
access the treatment. In addition, it is crucial to review
the reimbursement system for transplantation in other
countries in order to develop appropriate package for
the Thai context.
Conclusion
RI-HSCT is considered a curative option for adolescence
and young adult with severe thalassemia as it is highly ef-
fective and cost-effective throughout the patient’s lifetime.
Clinicians and policy makers may consider including RI-
HSCT in the health-benefit package given the long-term
value for money of this intervention.
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